Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

→ What President Biden's new law means for investors (From Stansberry Research) (Ad)
Free OPNT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$20.03
▼
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
OPNT stock logo

About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

OPNT Stock News Headlines

April 18, 2024 | investing.com
Hikma Pharmaceuticals PLC ADR (HKMPY)
January 31, 2024 | forbes.com
Ionis Pharmaceuticals
May 24, 2023 | msn.com
UPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdoses
May 23, 2023 | msn.com
REFILE-US FDA approves Opiant's overdose reversal spray
March 3, 2023 | msn.com
Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio
February 22, 2023 | finance.yahoo.com
Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%
February 7, 2023 | finance.yahoo.com
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
January 26, 2023 | seekingalpha.com
Horizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)
January 19, 2023 | finance.yahoo.com
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
January 14, 2023 | thetimes.co.uk
Dechra Pharmaceuticals defies cooling pets market
January 13, 2023 | seekingalpha.com
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
January 7, 2023 | businesswire.com
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...
November 22, 2022 | finance.yahoo.com
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
November 15, 2022 | benzinga.com
OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals
November 15, 2022 | benzinga.com
EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT
November 14, 2022 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indivior
November 14, 2022 | benzinga.com
OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders
November 14, 2022 | nasdaq.com
Indivior To Buy Opiant For $145 Mln In Cash
November 14, 2022 | seekingalpha.com
Opiant surges 123% as Indivior set to acquire overdose therapy maker for $145M
November 14, 2022 | marketwatch.com
Opiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNT
November 14, 2022 | finance.yahoo.com
Indivior PLC to Acquire Opiant Pharmaceuticals
November 14, 2022 | finance.yahoo.com
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
November 14, 2022 | finance.yahoo.com
Narcan Owner Opiant to Be Acquired by Indivior for $145 Million
November 2, 2022 | finance.yahoo.com
The past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitable
October 27, 2022 | finance.yahoo.com
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
See More Headlines

Company Calendar

Last Earnings
11/11/2021
Today
5/20/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPNT
CUSIP
N/A
CIK
1108924
Web
www.opiant.com
Phone
(310) 598-5410
Fax
917-322-2105
Employees
37
Year Founded
2009

Profitability

EPS (Most Recent Fiscal Year)
($6.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%
Return on Equity
-97.03%
Return on Assets
-59.66%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
5.48
Quick Ratio
5.48

Sales & Book Value

Annual Sales
$47.78 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
24.75
Book Value
$9.92 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
5,270,000
Free Float
3,865,000
Market Cap
$108.83 million
Optionable
Not Optionable
Beta
0.84

Social Links


OPNT Stock Analysis - Frequently Asked Questions

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced its quarterly earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.15 by $0.41. The technology company had revenue of $16.34 million for the quarter, compared to the consensus estimate of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%. During the same quarter in the previous year, the business earned $0.15 EPS.

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group Public (VOD), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and CyberArk Software (CYBR).

This page (NASDAQ:OPNT) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Elon to Transform U.S. Economy?
Porter & Company
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts